Do you want to read an article? Please log in or register.
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
Psoriatic Arthritis
Related content
PsoriasisPsoriatic Arthritis
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Ann Rheum Dis.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group
doi: 10.1136/
COMMENTED
Psoriatic Arthritis
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Ann Rheum Dis.
Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, SPIRIT H2H study group.
doi: 10.1136/annrheumdis-2019-215386.
Psoriatic Arthritis
Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
Arthritis Res Ther.
Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA, Mease PJ
doi: 10.1186/s13075-018-1769-7.
Psoriatic Arthritis
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).
Ann Rheum Dis.
Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, Pricop L, Mpofu S; FUTURE 1 study group
doi: 10.1136/
Psoriatic Arthritis
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
Rheumatology (Oxford).
Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, Burgos-Vargas R, Erickson JS, Rathmann SS, Sprabery AT, Birt JA, Shuler CL, Gallo G
doi: 10.1093/rheumatology/kez684.
Rheumatoid Arthritis
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
RMD Open.
Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R
doi: 10.1136/rmdopen-2016-000416.
Psoriatic ArthritisRheumatoid ArthritisSpinal Disorders
Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
Rheumatol Int.
Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH
doi: 10.1007/s00296-018-4180-4.
PsoriasisPsoriatic Arthritis
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
Rheumatology (Oxford).
Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P
doi: 10.1093/rheumatology/
COMMENTED
Rheumatoid Arthritis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Arthritis Res Ther.
Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR
doi: 10.1186/s13075-018-1614-z.